This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital Diaphragmatic Hernia (CDH)선천성 횡격막탈장 (선천성횡격막탈장)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q79.0 (congenital diaphragmatic hernia) | Special Copayment Reduction: V155
B. SynonymsCongenital diaphragmatic hernia, CDH, congenital diaphragmatic defect, Bochdalek hernia (left), Morgagni hernia (right anterior)
C. Adult onsetLikelihood of first presentation in adulthood very low — most are diagnosed by fetal ultrasound or by respiratory failure immediately after birth. Mild Morgagni hernias are sometimes found incidentally in adults, but typical CDH is in principle diagnosed in the neonatal period.
1. HistoryFirst described by Riverius in 1679 → Morgagni described the anterior hernia in 1769 → Bochdalek described the posterolateral defect in 1848 → first successful surgical repair by Ladd and Gross in 1946 → introduction of ECMO (1975) → FETO fetal intervention (2004–).
2. CausesComplex gene-environment interaction. Chromosomal abnormalities or single-gene variants in about 30–40%. Associated with disruption of retinoic acid signaling (STRA6, ZBTB16, etc.) and WT1, GATA4, NKX2-5 variants.
3. GeneticsAssociated genetic abnormalities (chromosomal nondisjunction, microdeletions, single-gene variants) in about 30–40%. CHD7, WT1, GATA4 variants. Most are sporadic.
4. General epidemiologyAbout 1 in 2,500–5,000 births. Left (Bochdalek) 80%, right 15–20%, bilateral 1–2%. About 10,000–20,000 cases annually worldwide. Survival at tertiary centers about 70%.
5. PathophysiologyFetal diaphragmatic defect → herniation of organs (stomach, small intestine, colon, spleen, liver) into the thorax → lung compression → reduced alveolar number and abnormal vascular development → pulmonary hypoplasia + persistent pulmonary hypertension (PPHN).
6. SymptomsSevere respiratory distress immediately after birth, cyanosis, barrel chest, scaphoid abdomen. Auscultation: bowel sounds in the chest. Rightward cardiac displacement.
7. SignsChest X-ray: bowel shadows in the thorax, rightward cardiac displacement, pulmonary hypoplasia. Prenatal ultrasound: stomach, small intestine, and liver identified in the thorax. Lung-to-head ratio (LHR) and total fetal lung volume (TFLV) indices are used to predict severity.
8. ScreeningBasic screening by prenatal ultrasound (18–22 weeks of gestation). If detected, associated abnormalities are evaluated by fetal MRI and prenatal genetic testing (chromosomes, CMA, WES).
9. DiagnosisPrenatal: ultrasound + fetal MRI + genetic testing. Postnatal: chest X-ray, blood gas analysis, echocardiography (PPHN evaluation), CT if needed.
10. TreatmentNeonatal stabilization (lung-protective ventilation, iNO, sildenafil, ECMO) → surgical diaphragmatic repair → fetal intervention (FETO: severe cases) → follow-up of long-term complications.
11. PrognosisOverall survival at tertiary centers about 70%. Liver herniation and low lung-to-head ratio are poor prognostic factors. Long-term complications in survivors: abnormal lung development, gastroesophageal reflux, neurodevelopmental abnormalities.
12. PreventionPlanned delivery at a specialist tertiary center after prenatal diagnosis. Prenatal diagnosis of associated chromosomal abnormalities. Avoid excessive retinoid exposure during pregnancy. FETO fetal intervention (severe cases).
13. ReferencesDeprest JA et al. FETO clinical studies, Stege G et al. CDH epidemiology … and 9 other papers

1. History

The history of congenital diaphragmatic hernia (CDH) dates back to the 17th century. In 1679, the French physician Lazare Riverius first described it after finding the stomach and small intestine herniated into the thorax at the autopsy of a deceased newborn. In 1769, the Italian anatomist Giovanni Battista Morgagni described herniation through an anterior retrosternal diaphragmatic defect, and this type is today called 'Morgagni hernia' after him. In 1848, the Czech anatomist Vincent Alexander Bochdalek systematically described herniation through a posterolateral diaphragmatic defect, the most common form, and this defect is today called the 'Bochdalek foramen.'

The history of surgical treatment began in the 20th century. In 1902, Heidenhain succeeded in surgically repairing CDH in an adult, and in 1946 the American pioneers of pediatric surgery William Ladd and Robert Gross achieved the first successful surgical repair of CDH in a newborn. Subsequently, as neonatal surgical techniques developed in the 1950s–60s, CDH repair became widespread, but mortality from pulmonary hypoplasia and persistent pulmonary hypertension (PPHN) remained high, limiting treatment outcomes.

In 1975, Bartlett in the United States introduced extracorporeal membrane oxygenation (ECMO) into CDH treatment, and survival of severe patients with serious pulmonary hypertension began to improve. In 1992, inhaled nitric oxide (iNO) was introduced for the treatment of PPHN, and since the 2000s the treatment paradigm has shifted with the establishment of lung-protective ventilation strategies and the concept of delayed surgical repair (delayed repair after hemodynamic stabilization). Since 2004, centered in Europe (the EUROFOETUS group), fetoscopic endoluminal tracheal occlusion (FETO) began to be performed at the clinical research stage in fetuses with severe CDH, and the FETO clinical trial in severe left CDH (TOTAL trial) has now been completed, reporting improved survival. In Korea as well, intensive CDH treatment and ECMO are performed in the pediatric surgery departments of major tertiary hospitals such as Asan Medical Center and Severance Hospital, and medical cost support is provided as a Special Copayment Reduction (V155) condition.

2. Causes

The causes of congenital diaphragmatic hernia are complex and are understood to arise from the interaction of genetic and environmental factors. About 40–60% of CDH occurs sporadically, with no clear genetic cause identified. In the remaining about 30–40%, chromosomal abnormalities, single-gene variants, or copy number variants (CNV) are present.

The most commonly associated chromosomal abnormalities are Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), Turner syndrome (45,X), and microdeletion/duplication syndromes of 1q, 4p, 15q, and others. CDH with associated chromosomal abnormalities tends to have a worse prognosis. Single-gene variants reported to be associated with CDH include GATA4 (a transcription factor involved in cardiac and diaphragmatic development), WT1 (associated with Denys-Drash syndrome), ZBTB16 (a retinoic acid receptor–binding transcription factor), STRA6 (retinoic acid receptor), COUP-TFII (NR2F2), and FZD4.

Abnormalities in the retinoic acid (RA) signaling pathway are known to play an important role in the development of CDH. Both vitamin A (retinol) deficiency and excessive retinoid exposure (teratogen) during pregnancy cause CDH in animal models. Retinoic acid regulates the expression of transcription factors involved in diaphragm development, such as GATA4 and WT1, and abnormalities in this pathway are proposed to lead to impaired diaphragmatic muscle formation. Suspected environmental risk factors include use of retinoid drugs during pregnancy (isotretinoin, etc.), exposure to pesticides (herbicides, fungicides), and exposure to some drugs, but clearly proven environmental risk factors remain limited to date. CDH can present as a component of several genetic syndromes, including CHARGE syndrome, Fryns syndrome, and Pallister-Killian syndrome.

3. Genetics

The genetics of congenital diaphragmatic hernia are complex and heterogeneous. Familial occurrence (familial CDH) is identified in only about 2% of all CDH patients, and most cases are sporadic. The recurrence risk of sporadic CDH in siblings is known to be about 2%. CDH as a single-gene disorder occurs with various inheritance patterns (autosomal dominant, recessive, X-linked). GATA4 variants are associated in an autosomal dominant manner with CDH and congenital heart malformations, and WT1 variants are associated with Frasier syndrome and Denys-Drash syndrome, which include nephropathy, genitourinary malformations, and CDH.

Chromosomal microarray analysis (CMA) is used in CDH patients to detect pathogenic CNVs beyond standard karyotyping. Whole-exome sequencing (WES) is useful for identifying single-gene causes, and recent studies report that pathogenic variants were identified by WES in about 20–30% of CDH patients. With the future spread of whole-genome sequencing (WGS), identification of the genetic causes of CDH is expected to improve further.

In genetic counseling, because the recurrence risk of sporadic CDH (about 2% in siblings) is low but not negligible, careful fetal anatomical examination by prenatal ultrasound is recommended when pregnant with a sibling of a CDH patient. When an associated genetic abnormality is found, the recurrence risk is assessed according to the inheritance pattern of that abnormality, and genetic counseling is provided. When familial CDH is suspected, genetic testing of the parents and siblings is considered. When there are associated malformations or a genetic syndrome, comprehensive counseling on prognosis and the appropriateness of aggressive treatment is needed.

4. General epidemiology

Congenital diaphragmatic hernia occurs in about 1 in 2,500–5,000 births, and an estimated 10,000–20,000 newborns are affected annually worldwide. Together with abdominal wall defects (omphalocele, gastroschisis), CDH is one of the most common congenital thoracoabdominal malformations. A difference in incidence by sex is unclear, though some studies have reported a slightly higher frequency in boys.

By anatomical distribution, left Bochdalek hernia accounts for about 80% of all CDH, right hernia about 15–20%, and bilateral hernia about 1–2%. Anterior Morgagni hernia accounts for about 2–3% of all diaphragmatic hernias, has relatively low clinical severity, and is sometimes found incidentally in adults. Right hernia is harder to diagnose prenatally than left because the liver masks the herniation, and it tends to have more severe pulmonary hypertension, so the prognosis is often poor.

Associated malformations are present in about 40–60% of CDH cases. The most common associated malformations are congenital heart malformations (about 20–40%), and genitourinary, central nervous system, and gastrointestinal malformations also occur. Isolated CDH without associated malformations has a relatively good prognosis. Overall survival at tertiary centers is reported to be about 70–80% in isolated CDH and about 40–50% with associated malformations. In Korea, CDH is eligible for rare disease Special Copayment Reduction (V155), providing support for surgical and intensive care costs. Data on CDH treatment outcomes at major domestic pediatric surgery centers are accumulating, and survival is reported to be generally similar to Western tertiary centers (about 70%).

5. Pathophysiology

The pathogenesis of congenital diaphragmatic hernia consists of a fetal diaphragmatic defect, the resulting herniation of abdominal organs into the thorax, and the consequent pulmonary hypoplasia and persistent pulmonary hypertension of the newborn (PPHN). These two pathologies are the main causes of death in CDH.

In the fetus, the diaphragm forms at 4–8 weeks of gestation; if a defect arises in the process of diaphragm formation separating the abdominal and thoracic cavities during this period, the Bochdalek foramen fails to close and remains as a defect. Through this defect, abdominal organs (mainly the small intestine, stomach, colon, spleen, and sometimes the liver) herniate into the thorax. When the herniated organs continuously compress the developing lung, lung branching and alveolar development are suppressed, resulting in pulmonary hypoplasia. Pulmonary hypoplasia may occur not only in the ipsilateral lung but also in the contralateral lung, and especially when the ipsilateral lung is severely hypoplastic, it is difficult to support breathing after birth with the contralateral lung alone.

Abnormal pulmonary vascular development is also an important pathophysiology. In CDH fetuses, the number of pulmonary vessels is reduced, and abnormal muscularization occurs in which the muscular layer of the developed pulmonary vessels becomes abnormally thick. This vascular abnormality prevents the normal postnatal fall in pulmonary vascular resistance, leading to PPHN. In PPHN, pulmonary artery pressure is equal to or higher than systemic arterial pressure, so right-to-left cardiac shunting (through the PDA and PFO) persists, causing severe hypoxemia. These pulmonary vascular abnormalities can persist even after diaphragmatic repair, so pulmonary vascular treatment is also important in postoperative management. Abnormalities in the retinoic acid signaling pathway are being studied as contributing not only to the diaphragmatic defect but also to abnormal pulmonary vascular development.

6. Symptoms

The clinical symptoms of congenital diaphragmatic hernia mostly appear in the neonatal period immediately after birth, with severe respiratory dysfunction as the main symptom. Even when already diagnosed by prenatal ultrasound, intensive treatment is needed immediately after birth. The severity of symptoms varies with the size of the diaphragmatic defect, the type of herniated organs (especially whether the liver is herniated), the degree of pulmonary hypoplasia, and the severity of PPHN.

The most prominent symptom immediately after birth is severe respiratory failure. Increased respiratory rate (tachypnea), chest retractions (chest wall and intercostal retractions), and cyanosis appear immediately, and oxygen saturation is not maintained with mask-and-bag resuscitation. On chest auscultation, breath sounds on the affected side (mainly left) are markedly decreased or absent, and bowel peristaltic sounds (bowel sounds) may be heard instead. Heart sounds are displaced to the side opposite the affected side (to the left in right-sided hernia). The abdomen appears flat or scaphoid (scaphoid abdomen) because abdominal organs have herniated into the thorax, reducing abdominal contents. The chest, conversely, appears distended in a barrel shape (barrel chest). This combination of symptoms (barrel chest + scaphoid abdomen + respiratory failure + cyanosis) is the characteristic clinical finding of CDH.

Symptoms mostly appear immediately after birth, but when the defect is small or herniation is delayed (late-presenting CDH), respiratory symptoms (recurrent pneumonia, cough, feeding difficulty) may appear after the neonatal period. Morgagni hernias often have a small, anteriorly located defect and are sometimes found incidentally on chest X-ray in adulthood without symptoms. When congenital heart malformations are present, additional symptoms of heart failure (edema, hepatomegaly, worsening cyanosis) may appear. Severe hypoxemia due to PPHN can cause neurological damage (brain injury), which is a cause of neurodevelopmental abnormalities after survival.

7. Signs

The physical and imaging signs of congenital diaphragmatic hernia play a key role in establishing the diagnosis and assessing severity. Signs found on prenatal ultrasound include ① bowel shadows in the thorax (stomach/bowel in the chest), ② displacement of the heart away from the affected side, ③ herniation of the liver into the thorax (liver seen within the thorax), ④ polyhydramnios (excess amniotic fluid due to esophageal and gastric dysfunction), and ⑤ marked reduction in the size of the ipsilateral lung.

The standard indices for predicting severity are the lung-to-head ratio (LHR) and total fetal lung volume (TFLV). The LHR is the cross-sectional area of the lung contralateral to the affected side divided by the head circumference; at 25 weeks of gestation, an LHR < 1.0 suggests a poor prognosis and > 1.5 a relatively good prognosis. Liver herniation (liver-up, liver herniated into the thorax) is an independent risk factor for poor prognosis. Fetal MRI is superior to ultrasound for accurate measurement of lung volume and identification of herniated organs, and is particularly useful for assessing intrathoracic liver herniation.

On postnatal chest X-ray, bowel shadows in the thorax (air-fluid levels), loss of the ipsilateral lung shadow, displacement of the heart away from the affected side, and loss of the diaphragmatic line on the affected side are observed. Diagnosis is relatively easy when the stomach or colon shadow is clearly seen on chest X-ray, but when the defect is small or only solid organs (liver, spleen) have herniated, X-ray findings may be nonspecific. Echocardiography is essential to assess the severity of PPHN (pulmonary artery pressure measurement, direction of intracardiac shunting) and associated congenital heart malformations. Blood gas analysis shows a mixed pattern of hypoxemia, hypercapnia, and respiratory and metabolic acidosis.

8. Screening

Prenatal screening for congenital diaphragmatic hernia is performed through the basic prenatal ultrasound at 18–22 weeks of gestation. In Korea, a fetal anatomical examination (anomaly scan) is performed as standard at this time as part of prenatal health checkups, detecting about 50–80% of CDH prenatally. When CDH is suspected or confirmed on ultrasound, the patient is immediately referred to a maternal-fetal medicine (MFM) specialist team at a higher-level tertiary center for detailed evaluation.

Additional screening tests after prenatal diagnosis of CDH consist of ① detailed fetal ultrasound (evaluation of associated malformations), ② fetal echocardiography (evaluation of congenital heart malformations), ③ fetal MRI (quantification of lung volume, assessment of liver herniation), and ④ genetic testing (chromosomal karyotyping, CMA, WES if needed). Because genetic abnormalities accompany about 30–40% of CDH patients, prenatal genetic testing is especially important when there are associated malformations or the ultrasound findings are severe. Fetal DNA is obtained by chorionic villus sampling (CVS) or amniocentesis for testing.

When prenatal screening has not been performed, clinical suspicion arises in the newborn immediately after birth from clinical findings (barrel chest, scaphoid abdomen, respiratory failure, cyanosis), and a chest X-ray is performed immediately for diagnosis. All medical staff treating newborns with respiratory failure in the neonatal intensive care unit (NICU) should be familiar with the clinical features of CDH so they can suspect it early and treat it immediately. Early diagnosis and prompt transfer to a specialist center directly affect survival.

9. Diagnosis

The final diagnosis of congenital diaphragmatic hernia is made by clinical findings, imaging findings, and genetic testing if needed. A clinical diagnosis is possible when bowel shadows in the thorax, cardiac displacement, and pulmonary hypoplasia are confirmed on prenatal ultrasound. Fetal MRI is performed for confirmation and is superior to ultrasound for quantifying lung volume, identifying herniated organs, and assessing intrathoracic liver herniation. The lung-to-head ratio (LHR) and observed/expected total fetal lung volume (o/e TFLV) are used to predict severity and determine indications for fetal intervention (FETO).

Postnatal diagnosis is confirmed by chest X-ray. The diagnosis is clear when bowel shadows in the thorax (air-fluid levels) and gastrointestinal air shadows are seen. The diagnosis is certain when, after insertion of a nasogastric tube, the X-ray shows the tip of the tube in the thorax. Echocardiography is essential to assess PPHN severity (pulmonary artery systolic pressure, direction and fraction of right-to-left shunting), associated cardiac malformations, and cardiac function, and is also important for determining ECMO indications. Blood gas analysis quantitatively assesses oxygenation and carbon dioxide ventilation, and the oxygenation index (OI = MAP × FiO₂ × 100 / PaO₂) is the main indicator for ECMO indications. CT may be used in a stable state for anatomical evaluation such as the size of the diaphragmatic defect and the composition of herniated organs, and for surgical planning.

Differential diagnoses include cystic lung malformations (CCAM, CPAM), congenital lobar emphysema, pleural effusion, and pulmonary sequestration, but most can be distinguished by the typical clinical and imaging findings of CDH. Genetic testing (chromosomal karyotype, CMA, WES) is performed to evaluate associated genetic syndromes, which is important for prognostic assessment and family counseling.

10. Treatment

Treatment of congenital diaphragmatic hernia consists of intensive neonatal stabilization, surgical diaphragmatic repair, and fetal intervention (in severe cases). The treatment goals are to maximize survival and minimize complications by controlling pulmonary hypertension, maintaining optimized lung ventilation, and performing surgical repair at the appropriate time.

Neonatal stabilization immediately after birth: when CDH is diagnosed prenatally, planned delivery is performed at a specialist tertiary hospital, and a resuscitation team should be on standby in the delivery room. Endotracheal intubation is performed immediately after birth, and mask positive-pressure ventilation is contraindicated because it worsens bowel distension. A nasogastric tube is inserted immediately for gastric decompression. In the neonatal intensive care unit (NICU), a lung-protective ventilation strategy is used—peak inspiratory pressure < 25 cmH₂O, tidal volume 4–6 mL/kg, permissive hypercapnia (PaCO₂ 45–60 mmHg, pH > 7.25)—to minimize barotrauma. For treatment of pulmonary hypertension (PPHN), inhaled nitric oxide (iNO) 20 ppm is used, together with pulmonary vasodilators such as sildenafil and milrinone given intravenously or orally.

Extracorporeal membrane oxygenation (ECMO): indicated in severe PPHN when oxygenation cannot be maintained despite maximal medical treatment. An oxygenation index (OI) > 40 or cardiac dysfunction due to pulmonary hypertension are the main indications. During ECMO, the lungs are rested as much as possible and hemodynamic stabilization is achieved before surgical repair. ECMO survival is about 50–60%, and it is the last resort for survival in severe CDH. Centers in Korea with experience performing ECMO for CDH are limited, and appropriate patient transfer and intensive care coordination are needed.

Surgical diaphragmatic repair: delayed repair is performed after hemodynamic stabilization (usually within 24–96 hours after birth). Through a laparotomy or thoracoscopic approach, the herniated organs are reduced into the abdominal cavity, and the diaphragmatic defect is repaired by primary suture or a prosthetic patch (synthetic patch, fascial patch). Patch repair is used when the defect is large or there is insufficient tissue, and the risk of recurrence after patch repair is higher than after primary suture. Even after surgery, PPHN management, treatment of gastroesophageal reflux, and nutritional support (establishment of enteral nutrition) are provided intensively.

Fetal intervention: fetoscopic endoluminal tracheal occlusion (FETO): in severe left CDH (o/e LHR < 25%, with liver herniation), a balloon is inserted into the fetal trachea using a fetoscope at 27–30 weeks of gestation to temporarily occlude the airway. The principle is that fluid accumulating in the fetal lungs promotes lung growth. The balloon is removed at 34 weeks of gestation. The TOTAL trial (2019) reported that FETO significantly improved survival in severe left CDH (40% vs. 15%), and clinical application is currently expanding at specialist centers. In Korea, some tertiary hospitals are building the capacity to perform FETO.

11. Prognosis

The prognosis of congenital diaphragmatic hernia has improved steadily over the past several decades, but it remains a serious disease with high neonatal mortality and various long-term complications in survivors. Overall survival at specialist tertiary centers is reported to be about 70–80% in isolated CDH and about 40–50% with associated malformations. However, because of selection bias in which a considerable portion of deaths does not include cases where active treatment was abandoned before or immediately after delivery, the actual survival of all CDH (including all cases) is estimated at about 50–60%.

Poor prognostic factors include ① liver herniation (liver-up): survival falls to 50% or less when the liver is herniated into the thorax, ② o/e LHR < 25% (extreme pulmonary hypoplasia), ③ bilateral CDH, ④ associated cardiac malformations, ⑤ associated chromosomal abnormalities, and ⑥ severe PPHN meeting ECMO indications. Survival in patients treated with ECMO is about 50–60%.

Long-term complications in survivors are an important clinical challenge. On the pulmonary side, chronic lung disease (bronchopulmonary dysplasia, BPD-like), reduced lung function during exercise, persistent pulmonary hypertension, and recurrent respiratory infections occur. On the gastrointestinal side, gastroesophageal reflux (GERD) occurs in about 50–80% of survivors, and many require antireflux surgery (Nissen fundoplication). Nutritional disorders and growth delay are also common. On the neurodevelopmental side, delays in cognitive, language, and motor development are reported in about 30–50% of survivors, explained by combined causes of postnatal hypoxia, ECMO, and repeated hospitalizations. Regular multidisciplinary follow-up (pediatric surgery, pediatric pulmonology, pediatric gastroenterology, developmental pediatrics, pediatric neurology, nutrition) is recommended.

12. Prevention

There is currently no established method to prevent the occurrence of congenital diaphragmatic hernia itself. However, prenatal diagnosis and planned delivery at a specialist tertiary hospital are the most important 'prognosis-improving' strategies for improving neonatal survival. When CDH is diagnosed prenatally, the patient should be immediately referred to a maternal-fetal medicine team, and delivery should be planned at a tertiary center equipped with NICU, pediatric surgery, and pediatric intensive care teams. This allows optimal treatment to begin immediately after birth and significantly improves survival.

Because use of retinoid drugs (isotretinoin, high-dose vitamin A preparations, etc.) during pregnancy is associated with an increased risk of CDH, they should not be used without a physician's prescription during pregnancy or when planning pregnancy. Minimizing exposure to pesticides and organic solvents during pregnancy is recommended, but to date no specific method of avoiding environmental exposure has been proven effective in preventing CDH.

In severe CDH (o/e LHR < 25%, with liver herniation), FETO (fetoscopic endoluminal tracheal occlusion) is a fetal intervention that promotes lung growth to improve postnatal survival, and the 2020 TOTAL trial demonstrated improved survival in severe left CDH. This is not a strategy to prevent CDH itself but to improve lung development and mitigate postnatal complications. When an associated genetic abnormality is identified, recurrence risk and prevention strategies (PGT, etc.) are discussed through genetic counseling appropriate to that genetic condition. When a previous child with CDH has been born, intensive surveillance with detailed prenatal ultrasound and fetal MRI is recommended in the next pregnancy.

13. References

  1. Deprest JA, Nicolaides KH, Benachi A, et al. Randomized trial of fetal surgery for severe left diaphragmatic hernia (TOTAL). N Engl J Med. 2021;385(2):107-118. DOI: 10.1056/NEJMoa2027030. PMID: 34260844.

  2. Stege G, Fenton A, Jaffray B. Nihilism in the 1990s: the true mortality of congenital diaphragmatic hernia. Pediatrics. 2003;112(3):532-535. DOI: 10.1542/peds.112.3.532. PMID: 12949281.

  3. Harting MT, Lally KP. The Congenital Diaphragmatic Hernia Study Group registry update. Semin Fetal Neonatal Med. 2014;19(6):370-375. DOI: 10.1016/j.siny.2014.09.003. PMID: 25263546.

  4. Snoek KG, Reiss IK, Greenough A, et al. Standardized postnatal management of infants with congenital diaphragmatic hernia (CDH). Neonatology. 2016;110(1):66-74. DOI: 10.1159/000444320. PMID: 27060661.

  5. Doyle NM, Lally KP. The CDH Study Group and its role in the development of CDH-related mortality and morbidity statistics. Semin Perinatol. 2004;28(2):93-100. DOI: 10.1053/j.semperi.2003.10.014. PMID: 15200249.

  6. Congenital Diaphragmatic Hernia Study Group; Lally KP, Lally PA, Lasky RE, et al. Defect size determines survival in infants with congenital diaphragmatic hernia. Pediatrics. 2007;120(3):e651-657. DOI: 10.1542/peds.2006-3040. PMID: 17766510.

  7. Wynn J, Yu L, Chung WK. Genetic causes of congenital diaphragmatic hernia. Semin Fetal Neonatal Med. 2014;19(6):324-330. DOI: 10.1016/j.siny.2014.09.003. PMID: 25263546.

  8. Reiss I, Schaible T, van den Hout L, et al. Standardized postnatal management of infants with congenital diaphragmatic hernia in Europe: the CDH EURO Consortium consensus. Neonatology. 2010;98(4):354-364. DOI: 10.1159/000297775. PMID: 20551688.

  9. Burgos CM, Frenckner B. Addressing the hidden mortality in CDH: a population-based study. J Pediatr Surg. 2017;52(4):522-525. DOI: 10.1016/j.jpedsurg.2016.08.020. PMID: 27639283.

  10. Putnam LR, Tsao K, Lally KP, et al. Minimally invasive vs open congenital diaphragmatic hernia repair: is there a superior approach? J Am Coll Surg. 2017;224(4):416-422. DOI: 10.1016/j.jamcollsurg.2016.12.021. PMID: 28065843.